Capacity scale-ups to drive Epigral's ₹5,000 crore target by FY31: CMD Maulik Patel
AI Summary
Epigral's ambitious revenue target of ₹5,000 crore by 2030-31, driven by significant capacity expansions in CPVC Resin and ECH, signals a strong growth trajectory in the specialty chemicals sector. For retail investors, this expansion not only highlights Epigral's commitment to becoming a leader in import-substituting chemicals but also positions the company favorably amid rising domestic demand. With a focus on sustainable production methods, Epigral may attract environmentally-conscious investors, making it a noteworthy consideration in the Indian specialty chemicals market.
Specialty chemicals manufacturer Epigral is targeting revenue of ₹5,000 crore by 2030-31, driven by upcoming production scale-ups in CPVC Resin and Epichlorohydrin (ECH), a senior company executive said.
The company expects to reach ₹2,900 crore in revenue this fiscal year following revenue of ₹2,500–2,530 crore in 2026.
Original Article
Published on Hindu BusinessLine
Frequently Asked Questions
What is this article about?
This is a company news update from Hindu BusinessLine, published on 27 September 2026.
Is this news positive or negative for markets?
TopFund's automated sentiment analysis reads this article as neutral in tone, based on the language used in the report. This is a general signal, not investment advice.
Where can I read the full article?
The full article is available at the original source, Hindu BusinessLine — see the "Read Original Article" link on this page.